Free Trial

Rapt Therapeutics (RAPT) Competitors

Rapt Therapeutics logo
$12.65 -1.29 (-9.25%)
Closing price 04:00 PM Eastern
Extended Trading
$13.10 +0.45 (+3.52%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT vs. PGEN, ARVN, TBPH, SAGE, ORGO, TSHA, ABVX, BCYC, BCAX, and ORKA

Should you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Abivax (ABVX), Bicycle Therapeutics (BCYC), Bicara Therapeutics (BCAX), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.

Rapt Therapeutics vs. Its Competitors

Rapt Therapeutics (NASDAQ:RAPT) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Rapt Therapeutics had 4 more articles in the media than Precigen. MarketBeat recorded 7 mentions for Rapt Therapeutics and 3 mentions for Precigen. Precigen's average media sentiment score of 0.91 beat Rapt Therapeutics' score of 0.34 indicating that Precigen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rapt Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Precigen
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rapt Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.

Precigen has higher revenue and earnings than Rapt Therapeutics. Precigen is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapt Therapeutics$1.53M136.75-$129.87M-$19.20-0.66
Precigen$3.92M120.48-$126.24M-$0.56-2.86

Rapt Therapeutics presently has a consensus target price of $21.67, suggesting a potential upside of 71.28%. Precigen has a consensus target price of $6.00, suggesting a potential upside of 275.00%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Rapt Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapt Therapeutics
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.43
Precigen
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Rapt Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Rapt Therapeutics' return on equity of -81.47% beat Precigen's return on equity.

Company Net Margins Return on Equity Return on Assets
Rapt TherapeuticsN/A -81.47% -70.24%
Precigen -3,728.87%-279.20%-79.74%

99.1% of Rapt Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 2.4% of Rapt Therapeutics shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Precigen beats Rapt Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Rapt Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RAPT vs. The Competition

MetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$230.51M$3.06B$5.67B$9.49B
Dividend YieldN/A2.44%4.05%4.00%
P/E RatioN/A20.8627.9419.95
Price / Sales136.75246.06396.5882.68
Price / CashN/A41.9636.1958.45
Price / Book1.108.308.635.82
Net Income-$129.87M-$55.19M$3.24B$258.42M
7 Day Performance23.66%5.07%3.22%1.94%
1 Month Performance53.89%17.61%10.72%12.02%
1 Year Performance-49.96%7.03%34.94%20.80%

Rapt Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RAPT
Rapt Therapeutics
4.3365 of 5 stars
$12.65
-9.3%
$21.67
+71.3%
-42.9%$230.51M$1.53M0.0080News Coverage
Analyst Upgrade
PGEN
Precigen
4.0452 of 5 stars
$1.95
+6.6%
$6.00
+207.7%
+0.6%$575.60M$4.20M-3.48190News Coverage
ARVN
Arvinas
3.7558 of 5 stars
$7.87
+1.0%
$20.29
+157.8%
-73.8%$574.43M$263.40M-11.92420News Coverage
Upcoming Earnings
TBPH
Theravance Biopharma
1.7695 of 5 stars
$11.47
+1.5%
$16.60
+44.7%
+12.1%$573.50M$64.38M-9.72110
SAGE
Sage Therapeutics
3.3405 of 5 stars
$9.15
-1.3%
$8.75
-4.4%
-33.0%$572.97M$41.24M-1.58690Upcoming Earnings
ORGO
Organogenesis
4.2605 of 5 stars
$4.49
+4.4%
$6.00
+33.6%
+57.1%$569.56M$482.04M-26.41950
TSHA
Taysha Gene Therapies
3.7589 of 5 stars
$2.64
flat
$8.17
+209.3%
+17.5%$566.70M$8.33M-7.76180
ABVX
Abivax
2.6866 of 5 stars
$8.83
+6.8%
$31.00
+251.1%
+469.8%$560.44MN/A0.0061Trending News
Analyst Forecast
High Trading Volume
BCYC
Bicycle Therapeutics
3.7429 of 5 stars
$8.08
+1.0%
$25.00
+209.4%
-63.3%$559.54M$35.28M-2.57240
BCAX
Bicara Therapeutics
2.0354 of 5 stars
$10.18
+4.8%
$31.86
+213.0%
N/A$555.22MN/A0.0032
ORKA
Oruka Therapeutics
2.7729 of 5 stars
$14.70
+3.3%
$40.38
+174.7%
N/A$550.37MN/A-3.26N/ANews Coverage
Upcoming Earnings
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:RAPT) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners